


### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the specification:

#### Listing of Claims

Claims 1 -10. (Cancelled)

Claim 11. (Previously Presented) A compound of formula Ia or Ib



or its pharmaceutically acceptable salts, where

Ar is phenyl optionally substituted by one or more substituents selected from halogen,

C<sub>1</sub>-C<sub>8</sub>-alkyl, cyano or nitro;


X<sup>1</sup> is -S-, -S(=O)- or -S(=O)<sub>2</sub>-;

X<sup>2</sup> is -S-, -S(=O)- or -S(=O)<sub>2</sub>-;

m is 1, 2, 3 or 4;

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>8</sub>-alkyl optionally substituted by hydroxy, C<sub>1</sub>-C<sub>8</sub>-alkoxy, acyloxy, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, -N(R<sup>4</sup>)R<sup>5</sup>, -CON(R<sup>6</sup>)R<sup>7</sup> or by a monovalent cyclic organic group having 3 to 15 atoms in the ring system;

Q has the formula



where R<sup>a</sup> is C<sub>1</sub>-C<sub>8</sub>-alkylene,

or Q is -C(R<sup>b</sup>)(R<sup>c</sup>)- where R<sup>b</sup> and R<sup>c</sup> are independently C<sub>1</sub>-C<sub>8</sub>-alkyl

or R<sup>b</sup> and R<sup>c</sup> together form a C<sub>3</sub>-C<sub>10</sub>-cycloalkyl;

Y is oxygen or sulfur;

$R^2$  is hydrogen,  $C_1$ - $C_8$ -alkyl or  $C_3$ - $C_{10}$ -cycloalkyl and  $R^3$  is  $C_1$ - $C_8$ -alkyl substituted by phenyl, phenoxy, acyloxy or naphthyl, or  $R^3$  is  $C_3$ - $C_{10}$ -cycloalkyl optionally having a benzo group fused thereto, a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms, phenyl or naphthyl, said phenyl, phenoxy or naphthyl groups being optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, acyl, nitro,  $-SO_2NH_2$ ,  $C_1$ - $C_8$ -alkyl optionally substituted by  $C_1$ - $C_8$ -alkoxy,  $C_1$ - $C_8$ -haloalkyl,  $C_1$ - $C_8$ -alkoxy,  $C_1$ - $C_8$ -haloalkoxy,  $C_1$ - $C_8$ -alkylthio,  $-SO_2$ - $C_1$ - $C_8$ -alkyl,  $C_1$ - $C_8$ -alkoxycarbonyl,  $C_1$ - $C_8$ -acylamino optionally substituted on the nitrogen atom by  $C_1$ - $C_8$ -alkyl,  $C_1$ - $C_8$ -alkylamino, aminocarbonyl,  $C_1$ - $C_8$ -alkylamino-carbonyl, di( $C_1$ - $C_8$ -alkyl)amino, di( $C_1$ - $C_8$ -alkyl)aminocarbonyl, di( $C_1$ - $C_8$ -alkyl)aminocarbonyl-methoxy, or  $R^2$  and  $R^3$  together with the nitrogen atom to which they are attached denote a heterocyclic group having 5 to 10 ring atoms of which 1, 2 or 3 are hetero atoms;


$R^4$  and  $R^5$  are each independently hydrogen or  $C_1$ - $C_8$ -alkyl, or  $R^4$  is hydrogen and  $R^5$  is hydroxy- $C_1$ - $C_8$ -alkyl, acyl,  $-SO_2R^8$  or  $-CON(R^6)R^7$ , or  $R^4$  and  $R^5$  together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group;

$R^6$  and  $R^7$  are each independently hydrogen or  $C_1$ - $C_8$ -alkyl, or  $R^6$  and  $R^7$  together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group; and

$R^8$  is  $C_1$ - $C_8$ -alkyl,  $C_1$ - $C_8$ -haloalkyl, or phenyl optionally substituted by  $C_1$ - $C_8$ -alkyl.

Claim 12. (Currently Amended) A compound according to claim 11, which is

- (i) a compound of formula Ia or its pharmaceutically acceptable salts, wherein
- Ar is phenyl substituted by halo;
  - $X^1$  is  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;
  - m is 2;
  - $R^1$  is  $C_1$ - $C_8$ -alkyl optionally substituted by hydroxy or  $C_1$ - $C_8$ -alkoxy;
  - Y is oxygen;
  - $R^2$  is hydrogen; and
  - $R^3$  is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms; or
- (ii) a compound of formula Ib or its pharmaceutically acceptable salts, wherein
- Ar is phenyl substituted by halo;
  - ~~$X^2$  is  $-O-$ ,  $-C(=O)-$  or  $-CH_2-$ ;~~
  - m is 1 or 2;
  - Q has the formula



where  $R^a$  is  $C_1$ - $C_8$ -alkylene,

or Q is  $-C(R^b)(R^c)-$  where  $R^b$  and  $R^c$  are independently  $C_1$ - $C_8$ -alkyl

or  $R^b$  and  $R^c$  together form a  $C_3$ - $C_{10}$ -cycloalkyl;

$R^2$  is hydrogen; and

$R^3$  is a heterocyclic group having 5 to 11 ring atoms of which 1 to 4 are hetero atoms.

Claim 13. (**Currently Amended**) A compound according to claim 11, which is

(i) a compound of formula Ia or its pharmaceutically acceptable salts, wherein

Ar is phenyl substituted by halo, preferably chloro;

$X^1$  is  $-S-$ ,  $-S(=O)-$  or  $-S(=O)_2-$ ;

m is 2;

$R^1$  is  $C_1$ - $C_4$ -alkyl optionally substituted by hydroxy or  $C_1$ - $C_4$ -alkoxy;

Y is oxygen;

$R^2$  is hydrogen; and

$R^3$  is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -alkoxy or  $C_3$ - $C_6$ -cycloalkyl; or


(ii) a compound of formula Ib or its pharmaceutically acceptable salts, wherein

Ar is phenyl substituted by halo, preferably chloro;

~~$X^2$  is  $-O-$ ,  $-C(=O)-$  or  $-CH_2-$ ;~~

m is 1 or 2;

Q has the formula



where  $R^a$  is  $C_1$ - $C_8$ -alkylene,

or Q is  $-C(R^b)(R^c)-$  where  $R^b$  and  $R^c$  are independently  $C_1$ - $C_4$ -alkyl

or  $R^b$  and  $R^c$  together form a  $C_3$ - $C_6$ -cycloalkyl;

$R^2$  is hydrogen; and

R<sup>3</sup> is a heterocyclic group having 5, 6 or 7 ring atoms of which one, two, three or four, are hetero atoms selected from nitrogen, oxygen and sulphur, said heterocyclic group being optionally substituted by C<sub>1</sub>-C<sub>4</sub>-alkyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl.

Claim 14. (**Previously Presented**) A compound according to claim 11 or a pharmaceutically acceptable salt thereof that is selected from the group consisting of:

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(3,5-dimethoxy-phenyl)-urea;

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-[1,3,4]thiadiazol-2)-urea;

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-isoxazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-benzenesulfinyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(3-ethyl-isoxazol-5-yl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(3,5-dimethoxy-phenyl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(5-ethyl-isoxazol-3-yl)-urea;

1-((S)-3-[3-(4-Chloro-phenylsulfanyl)-azetidin-1-yl]-1-hydroxymethyl-propyl)-3-(3-ethyl-isoxazol-5-yl)-urea;

1-[(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(5-ethyl-[1,3,4]thiadiazol-2-yl)-urea;

1-[(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-[(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea;

1-[(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(3,5-dimethoxy-phenyl)-urea;

1-[(S)-3-[3-(4-Chloro-benzenesulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(5-ethyl-isoxazol-3-yl)-urea; and

1-[(S)-3-[3-(4-Chloro-benzene-sulfonyl)-azetidin-1-yl]-1-hydroxymethyl-propyl]-3-(3-ethyl-isoxazol-5-yl)-urea.

**Claim 15. (Previously Presented)** A pharmaceutical composition comprising a compound according to claim 11 or a pharmaceutically acceptable salt thereof in combination with another drug substance selected from an anti-inflammatory, a bronchodilator, an antihistamine or an anti-tussive substance.

**Claim 16. (Previously Presented)** A pharmaceutical composition comprising as active ingredient a compound according to claim 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.


**Claim 17. (Previously Presented)** A pharmaceutical composition comprising as active ingredient a compound according to claim 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

**Claim 18. (Withdrawn – Currently Amended):** A method of treating a condition mediated by CCR-3 in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of Claim 11, formula I or a pharmaceutically acceptable salt thereof.


Claim 19. **(Withdrawn – Currently Amended)**: A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of Claim 11, formula-I or a pharmaceutically acceptable salt thereof.

Claim 20. **(Withdrawn-Currently Amended)**: A process for the preparation of a compound of formula Ia or Ib as claimed in claim 11 which comprises

- (i) (A) for the preparation of compounds of formula Ia where R<sup>2</sup> is hydrogen, reacting a compound of formula IIa




or a protected form thereof, where Ar, X<sup>1</sup>, m and R<sup>1</sup> are as defined in claim 11, with a compound of formula III



where Y and R<sup>3</sup> are as defined in claim 11; or


- (B) for the preparation of compounds of formula Ia where Y is oxygen, reacting a compound of formula IIa where Ar, X<sup>1</sup>, m and R<sup>1</sup> are as defined in claim 11, with a compound of formula IV



where R<sup>2</sup> and R<sup>3</sup> are as defined in claim 11; or

- (C) for the preparation of compounds of formula Ia where X<sup>1</sup> is -S(=O)<sub>2</sub>-, oxidising a compound of formula Ia in protected form where X<sup>1</sup> is -S- and Ar, m, R<sup>1</sup>, Y, R<sup>2</sup> and R<sup>3</sup> are as defined in claim 11;

- (D) for the preparation of compounds of formula Ib, reacting a compound of formula IIb



where Ar,  $\text{X}^2$ , m and Q are as defined in claim 11, with a compound of formula IV  
where  $\text{R}^2$  and  $\text{R}^3$  are as defined in claim 11;

(E) for the preparation of compounds of formula Ib where  $\text{R}^2$  is hydrogen, reacting a  
compound of formula IIb where Ar,  $\text{X}^2$ , m and Q are as defined in claim 11, with a compound  
of formula V



where  $\text{R}^3$  is as defined in claim 11; or

(F) for the preparation of compounds of formula Ib where  $[\text{X}] \text{X}^2$  is  $-\text{S}(=\text{O})_2-$ , oxidising a  
compound of formula Ib in protected form where  $\text{X}^2$  is  $-\text{S}-$  and Ar, m, Q,  $\text{R}^2$  and  $\text{R}^3$  are as  
defined in claim 11; and

- (ii) recovering the product in free or salt form.